A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer.

Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2015

At a glance

  • Drugs Lorvotuzumab mertansine (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NORTH
  • Sponsors ImmunoGen
  • Most Recent Events

    • 25 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Nov 2013 Planned number of patients changed from 175 to 160 as reported by European Clinical Trials Database record.
    • 25 Oct 2013 Status changed from recruiting to active, no longer recruiting, as reported in an ImmunoGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top